George Trusov

Mr. George Trusov


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2019 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
ORO. A. Rachinskaya
O. A. Rachinskaya
GTGeorge Trusov
George Trusov
MKM. D. Khorolsky
M. D. Khorolsky
ISI. S. Semenova
I. S. Semenova
VMV. A. Merkulov
V. A. Merkulov
The manufacturer (developer) has to prepare a specification for each newly developed biomedical cell product (BCP) that has passed the stage of preclinical studies. The specification is included into the registration dossier when applying for marketing authorisation of a BCP. In accordance with the Order of the Ministry of Health of the Russian Federation No. 14n of 19 January 2017 «On approval of the specification format for a biomedical cell product» the specification should contain information about authenticity of the cell line used in the BCP, namely: morphological characteristics, expression of specific markers, expression of specific genes, expression of specific proteins, as well as markers of cell line stability. At present Russia has no practical experience in BCP quality evaluation. The aim of the study was to substantiate methodological approaches to authentication of cell lines used in BCPs as illustrated by quality evaluation of the DF-2 model cell line using test methods that allow for characterisation of the morphological, genetic, immunophenotypic, and cytogenetic profile of the cell line. Materials and methods: the study analysed the DF-2 cell line — human dermal fibroblasts (mesenchymal stem cells) obtained from the Institute of Cytology of the Russian Academy of Sciences (St. Petersburg). The following analytical test methods were used in the study: morphological analysis; flow cytometry for immunophenotyping of the DF-2 model cell line; short tandem repeats for creating an allelic profile of the model cell line; cytogenetic analysis — differential DAPI staining of metaphase chromosomes. Results: the paper summarises methodological approaches to identification testing of medicines containing living human cells (BCP analogues) currently used in international practice, and presents the results of authentication of the model cell line. Conclusions: methods used for BCP identification testing should ensure unambiguous authentication of the cell line according to its specification. The study performed helped to work out the procedure of authentication of a model cell line.

28 September 2018 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ЕМЕ. В. Мельникова
Е. В. Мельникова
AGA. A. Goryaev
A. A. Goryaev
MSM. V. Savkina
M. V. Savkina
OMO. V. Merkulova
O. V. Merkulova
ACAlexander Chaplenko
Alexander Chaplenko
VMV. A. Merkulov
V. A. Merkulov
The intensive development of cellular technologies stipulates the introduction at the global level of medicinal products based on viable human cells, which in most countries are referred to as biomedical cell products. The authors conducted a comparative analysis of the regulatory framework in different countries and determined special aspects of regulation of cell therapy products (analogues of biomedical cell products). Some countries have mechanisms for priority review of cell therapy products for marketing authorization, such as accelerated assessment, accelerated approval, or conditional marketing authorisation. These mechanisms are currently absent in Russia, because of the novelty of the regulatory framework, and the biological properties of innovative cell products. Biomedical cell products are regarded as a separate class of medicinal products in Russia, they are not treated as biologicals and are regulated by the Federal Law No. 180-FZ «On Biomedical Cell Products» of June 23, 2016. The main difference in regulation of cell-based products in the Russian Federation is the principle of unified requirements for marketing authorisation of autologous, allogeneic, and combined biomedical cellular products, and the absence of the «hospital exemptions» mechanism that exists in many countries. This mechanism allows prescription and use of personalised autologous medicines produced in the laboratory of a medical institution for a particular patient.

Verified
Journal Article
Open access
PDF file
DSDmitry Vitalievich Sosin
Dmitry Vitalievich Sosin
DBDenis Baranovskii
Denis Baranovskii
DNDenis Nechaev
Denis Nechaev
MSMariya Aleksandrovna Sosina
Mariya Aleksandrovna Sosina
ASAlexander Shaposhnikov
Alexander Shaposhnikov
Ilya D. KlabukovIlya D. Klabukov
Ilya D. Klabukov
The evolution of man on Earth took place under conditions of constant exposure to background ionizing radiation (IR). From this point of view, it would be reasonable to hypothesize the existence of adaptive mechanisms that enable the human organism to safely interact with IR at levels approximating long-term natural background levels. In some situations, the successful operation of molecular mechanisms of protection against IR is observed at values significantly exceeding the natural background level, for example, in cancer cells. In 15–25% of cancer patients, cancer cells develop a phenotype that is resistant to high doses of IR. While further investigations are warranted, the current evidence suggests a strong probability of observing positive health effects, including an increased lifespan, a reduced cancer risk, and a decreased incidence of congenital pathologies, precisely at low doses of ionizing radiation. This review offers arguments primarily based on a phenomenological approach and critically reconsidering existing methodologies for assessing the biological risks of IR to human health. Currently, in the most economically developed countries, there are radiation safety rules that interpret low-dose radiation as a clearly negative environmental factor. Nowadays, this approach may pose significant challenges to the advancement of radiomedicine and introduce complexities in the regulation of IR sources. The review also examines molecular mechanisms that may play a key role in the formation of the positive effects of low-dose IR on human radioadaptive capabilities.

15 May 2021 in Ekologiya cheloveka (Human Ecology)
Verified
Journal Article
Open access
PDF file
ATAnastasia G. Titova
Anastasia G. Titova
IZI. A. Zanyatkin
I. A. Zanyatkin
AVA. G. Volkova
A. G. Volkova
DND. N. Nechaev
D. N. Nechaev
GTGeorge Trusov
George Trusov
In this review article we provide an overview of epigenetic markers associated with the effects of particulate matter with different aerodynamic diameters, namely, PM0,1, PM, PM10 and PM2,5-10. The developed list of more than 150 epigenetic signatures of environmental pollutants on different human health conditions may contribute to the development of novel methodological approaches to early detection of diseases in individuals exposed to particulate matter. In addition, this work can become a prerequisite for the development of fundamentally new air purification systems.

20 August 2025 in Extreme Medicine
Verified
Journal Article
Open access
PDF file
ATAnastasia G. Titova
Anastasia G. Titova
GTGeorge Trusov
George Trusov
ABA. V. Bayov
A. V. Bayov
DSDmitry Vitalievich Sosin
Dmitry Vitalievich Sosin
DND. N. Nechaev
D. N. Nechaev
SYSergey Yudin
Sergey Yudin
Мировые репозитории, содержащие сведения о результатах популяционных иммунологических и генетических исследований

27 April 2025 in Russian Medicine
Verified
Journal Article
Closed access
AMArina Mishina
Arina Mishina
SBSiroj Ysufovich Bakoev
Siroj Ysufovich Bakoev
AKAnna Korobeinikova
Anna Korobeinikova
ATAnastasia Valerievna Tsypkina
Anastasia Valerievna Tsypkina
SKShuanat Shamilevna Kabieva
Shuanat Shamilevna Kabieva
ГВГетманцева Любовь Владимировна
Гетманцева Любовь Владимировна
Medicine of the 21st century has an extensive arsenal of means for diagnosing diseases. High-tech equipment can detect pathologies without clinical manifestations during the latent stage of disease development. Actigraphy is a portable device based on an accelerometer, used for tracking sleep parameters, and also, well established as a tool for monitoring the circadian rhythms of a person. Actigraphy is not an alternative to the use of polysomnography, however, it has advantages in ease of use, cost, and size of the device, in addition to allowing long-term continuous recording of night and daytime sleep over several days or weeks in the patient's home sleep environment. In addition to its primary function — the study of sleep characteristics — actigraphy is widely used as a method for detecting and monitoring diseases, including cognitive impairment, psychiatric disorders, cardiovascular pathologies, and respiratory diseases. In this review, we have compiled current information on actigraphy as a tool for disease diagnosis. The described results allow us to summarize the useful characteristics of such a diagnostic tool and shed light on applying this progressive and reliable method in medicine.